Skip to main content

Table 1 Demographic characteristics of patient groups using and not using migraine preventive treatments

From: Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

Patient characteristic (ITT population)

Using preventive treatments N = 698

Not using preventive treatments N = 3283

Age, mean (SD), years

45.7 (11.6)

41.4 (12.5)

Female, n (%)

613 (87.8)

2742 (83.5)

Race, white, n (%)

595 (85.2)

2560 (78.0)

BMI, mean (SD)

30.3 (7.3)

30.2 (8.8)

Duration of migraine history, mean (SD), years

21.4 (13.8)

18.1 (12.6)

Average migraine attacks/month in past 3 months, mean (SD)

5.3 (1.8)

5.2 (1.9)

  1. BMI body-mass index, ITT intent to treat, N number of patients in subgroup of ITT population, n number of patients with stated characteristic, SD standard deviation
  2. p < 0.05; p < 0.001 compared with not using preventives